Research Analysts Set Expectations for Alumis Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings per share (EPS) estimate for Alumis Inc. from ($0.74) to ($0.80), while maintaining a "Buy" rating and a price target of $14.00.
• Alumis reported a loss of ($1.17) EPS for the last quarter, missing the consensus estimate, but achieved revenues of $2.67 million, exceeding analyst expectations.
• Consensus estimates for Alumis' full-year earnings indicate a significant loss of ($8.51) per share, with various analysts providing differing price targets ranging from $17.00 to $25.00.

Alumis Inc. (NASDAQ:ALMS - Free Report) - Analysts at HC Wainwright lowered their Q3 2025 earnings estimates for Alumis in a research report issued to clients and investors on Thursday, August 14th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.80) for the quarter, down from their prior forecast of ($0.74). HC Wainwright has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis' Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($4.34) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.96) EPS and FY2026 earnings at ($3.49) EPS.

A number of other research analysts have also recently issued reports on ALMS. Wells Fargo & Company began coverage on shares of Alumis in a research note on Friday, July 25th. They issued an "overweight" rating and a $17.00 price objective on the stock. Guggenheim raised shares of Alumis to a "buy" rating and set a $18.00 price objective on the stock in a research note on Tuesday, June 10th. Wall Street Zen raised shares of Alumis from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 16th. Oppenheimer dropped their price objective on shares of Alumis from $26.00 to $25.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. Finally, Morgan Stanley dropped their price objective on shares of Alumis from $23.00 to $22.00 and set an "overweight" rating for the company in a research note on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat, Alumis has a consensus rating of "Buy" and a consensus target price of $20.17.

Alumis Stock Performance

NASDAQ:ALMS traded up $0.24 during mid-day trading on Monday, reaching $4.84. The stock had a trading volume of 692,407 shares, compared to its average volume of 745,538. The stock has a 50-day simple moving average of $3.73 and a two-hundred day simple moving average of $4.59. Alumis has a 12 month low of $2.76 and a 12 month high of $13.11.

Alumis (NASDAQ:ALMS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.06). The company had revenue of $2.67 million for the quarter, compared to analyst estimates of $1.80 million.

Institutional Investors Weigh In On Alumis

Institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new stake in Alumis during the 4th quarter worth approximately $108,000. Tang Capital Management LLC grew its holdings in Alumis by 40.6% during the 4th quarter. Tang Capital Management LLC now owns 600,000 shares of the company's stock worth $4,716,000 after acquiring an additional 173,406 shares during the last quarter. Foresite Capital Management V LLC grew its holdings in Alumis by 3.5% during the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company's stock worth $45,426,000 after acquiring an additional 194,459 shares during the last quarter. Barclays PLC grew its holdings in Alumis by 33.9% during the 4th quarter. Barclays PLC now owns 24,581 shares of the company's stock worth $193,000 after acquiring an additional 6,221 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Alumis by 4.3% during the 4th quarter. Northern Trust Corp now owns 111,326 shares of the company's stock worth $875,000 after acquiring an additional 4,587 shares during the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.